Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that integrates signals downstream of integrin and growth factor activation. Previously, we have shown that skin-specific loss of fak prevents chemically induced skin carcinogenesis in mice following phorbol ester treatment. In this study, we show that skinspecific deletion of fak prevents mobilization of stem cells within the bulge region of the hair follicle, which are the precursors of papillomas following phorbol ester treatment. We also show that phorbol ester treatment results in activation of-catenin within the skin and that FAK is required for β-catenin-induced stem cell mobilization. In addition, inhibition of Src kinase activity, a major binding partner of FAK also prevents stem cell mobilization. We show that FAK is required for the nuclear localization of β-catenin in the skin following phorbol ester treatment and the transcriptional activation of the β-catenin target gene c-Myc. This provides the first evidence of cross-talk between integrin and Wnt signalling pathways in the control of epidermal stem cells and the early events associated with skin carcinogenesis.
Introduction
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which is overexpressed in a number of epithelial tumours including breast, colon, hepatocellular carcinoma and squamous cell carcinomas of the head and neck, and in some cases, this has been associated with poor clinical outcome (1, 2) . FAK was initially identified as a regulator of integrin-dependent adhesions and cell motility and is known to regulate tumour cell invasion and metastasis, and much attention has, therefore, focused on its role in the later stages of tumour progression (3) (4) (5) . However, FAK is also important at early stages of tumour initiation. In mouse models of mammary tumourigenesis, FAK is required at the transition from premalignant lesions to carcinomas (6) , and we have shown using a two-stage skin carcinogenesis model that targeted deletion of fak in mouse skin prevents tumour formation (7) . In this model, treatment with the carcinogen dimethylbenzanthracene gives rise to H-ras mutations in keratinocytes within the bulge stem cell compartment of the hair follicle. Subsequent treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) results in the clonal expansion of these cells, which give rise to papillomas. Deletion of fak in the skin reduced both the number of mice that developed papillomas and the number of papillomas following TPA treatment (7) . However, nothing is known about how FAK regulates these early events in tumourigenesis.
The stem cell niche within the hair follicle is tightly regulated and one key pathway involved is the canonical Wnt signalling pathway (8) (9) (10) (11) . Binding of Wnt proteins to their receptors initiates a signalling cascade that results in stabilization of cytoplasmic β-catenin, which can translocate to the nucleus where it interacts with members of the T-cell factor (TCF)/Lef family of transcription factors to transactivate expression of target genes. In the skin, β-catenin regulates stem cell activation and epidermal cell fate. More recently, a role in the maintenance of cancer stem cells within the skin has been described and identifies the bulge-derived stem cells as the source of papillomas that develop in the chemically induced skin carcinogenesis model described above (12) .
We, therefore, used the skin to dissect out the role of FAK in the early stages of tumourigenesis. We provide evidence that FAK regulates TPA-induced β-catenin activation in the bulge region of the hair follicle by preventing its nuclear localization and transcriptional activation of key targets such as c-Myc. FAK is required for the ability of β-catenin to initiate the proliferation of stem cells within the bulge region of the hair follicle.
Materials and methods

Animals
K14/FAK
fl/fl mice were generated as described previously (7) . Catnb ∆ex3 mice were a kind gift from M.Taketo (Kyoto University, Kyoto, Japan), Fyn −/− and Yes −/− mice were from the Jackson Laboratory (B6.129S7-Fyn tm1Sor /J and 129-Yes tm1Sor /J, respectively) and Src fl/fl mice were a kind gift from WJ.Muller (McGill University, Montreal, Canada). Mice were genotyped by PCR analysis as described previously (7, 13, 14) . All experiments were carried out in accordance with the UK Animal Scientific Procedures Act (1986). About 6-8-week-old mice were injected with 0.1 mg 4-hydroxytamoxifen (4OHT) or sunflower oil (vehicle; Sigma, Poole, UK) daily for 5 days and after a further 10 days, 6.25 µg TPA or acetone (vehicle; Sigma) was given topically twice weekly in 150 µl of acetone for 2 weeks to either the dorsal skin or tail. AZD0530 (provided by AstraZeneca, Alderley Park, Macclesfield, UK) was given by daily gavage as indicated at a concentration of 10 mg/kg using 0.5% HPMC/0.1% polysorbate as a vehicle.
BrdU labelling
To generate label retaining cells (LRCs), 5-bromo-2-deoxyuridine (BrdU) (50 mg/kg; GE Healthcare) was injected into 4-day-old mice daily for 5 days. Mice were maintained for 50 (±10) days and then treated with 4OHT and TPA as described above in Animals section. AZD0530 or vehicle treatment was given by daily gavage from the first 4OHT injection day. K14/Catnb ∆ex3 mice were treated with BrdU to generate LRC as described above in Animals section but were culled 6 days after the first 4OHT injection.
Immunohistochemistry
Immunohistochemical analysis of dorsal skin samples was carried out as described previously (15) using Ki67 (1:100; Vector Labs, Peterborough, UK), FAK (1:500), Src (1:150; both Cell Signalling Technologies, Hitchin, UK) and c-Myc (1:500; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. Immunohistochemistry for β-catenin was performed on sections fixed in formaldehyde for no longer than 24 h as described in Batlle et al. (16) . After de-waxing in xylene and rehydrating slides in decreasing concentrations of ethanol, sections were blocked in 1.5% hydrogen peroxidase for 45 min. Antigen retrieval was performed in pre-heated Tris/ethylenediaminetetraacetic acid (pH 8.0) in a boiling water bath for 50 min. Slides were cooled at room temperature for 1 h and then blocked with 1% bovine serum albumin for 30 min. Primary antibody (β-catenin, 1:50; BD Biosciences, Oxford, UK) was added and slides were incubated at room temperature for 2 h. After washing slides in phosphate-buffered saline (PBS), they were incubated for 1 h with the horseradish peroxidase-labelled polymer (Envision+ Systemhorseradish peroxidase; Dako, Ely, UK). Positivity was visualized using diaminobenzidene (Envision+ System-horseradish peroxidase; Dako).
Preparation of whole tail mounts
To prepare whole mounts of tail epidermis, a scalpel was used to slit the tail length ways, the skin was peeled from the tail and incubated in 5 mM ethylenediaminetetraacetic acid/PBS at 37°C for 3 h. Forceps were used to gently peel the intact sheet of epidermis away from the dermis, with the epidermal tissue being fixed in neutral-buffered formaldehyde 10% v/v for 2 h at room temperature. Fixed epidermal sheets were washed three times with PBS and stored in PBS containing 0.2% sodium azide at 4°C prior to labelling.
Immunolabelling of tail mounts
Epidermal sheets were stained as described in Braun et al. (17) . In brief, epidermal sheets were blocked and permeabilized in permeabilization buffer (0.5% bovine serum albumin/0.5% Triton X in Tris-buffered saline) for 30 min at room temperature. Epidermal sheets were then incubated with 2 N HCl at 37°C for 20 min before addition of primary antibodies in permeabilization buffer: BrdU (1:200; Oxford Biotech Ltd, Oxford, UK) and K15 (1:200; NeoMarkers, Stratech Scientific, Newmarket, UK). After overnight incubation with the antibodies, the epidermal sheets were washed extensively with 0.2% Tween/PBS before addition of the appropriate species-specific Texas Red or fluorescein isothiocyanate conjugated secondary antibodies (1:400; Jackson ImmunoResearch, Stratech Scientific). Images were acquired at 2-µm intervals using an Olympus FV1000 confocal microscope with ×20 objective. Scans are presented as z-projections of around 30 optical sections. Analysis of BrdU-positive LRCs was carried out using the area plug-in in ImageJ from five representative images per mouse.
Isolation of primary keratinocytes and qRT-PCR
Keratinocytes were isolated as described previously (7) and plated on collagen I-coated cellware (BD Biosciences). Cells were treated with vehicle (PBS) or 100 ng/ml recombinant mouse Wnt3a (Millipore) for 3 h prior to RNA extraction.
RNA was extracted using the Qiagen RNA extraction kit as per manufacturer's instructions and treated with DNase1 (Turbo-DNase kit, Ambion) prior to quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Samples were diluted to a stock concentration of 200 ng/μl and qRT-PCR was performed using a SensiMix SYBR one step kit (Quantace) as per manufacturer's instructions and processed using a Rotorgene RG-3000 (Corbett Research). Results were analysed using Rotorgene 6 software (Corbett Research) and normalized to β-2-microglobulin levels. Primer sequences were as follows: axin2 F: GCTCCAGAAGATCACAAAGAGC, R: AGCTTTGAGCCTTCAGCATC; Tcf7 F: CACCACAGGAGGAAAAAGAAATG, R: CAAGGAGGGCAAC AGAAGATAC; Myc F: TGAAGAAGAGCAAGAAGATGAG, R: CTGGAT AGTCCTTCCTTGTG and B2M F: GGGAAGCCGAACATACTGAA, R: TGCTTAACTCTGCAGGCGTAT.
Results
FAK regulates TPA-induced changes in epidermal hyperplasia
Treatment with TPA leads to epidermal hyperplasia and as FAK is required for dimethylbenzanthracene/TPA-driven skin carcinogenesis, we first looked at the role of FAK in these TPA-induced changes in the skin. Cohorts of K14CreER T2 (K14) and K14CreER epidermal-specific deletion of fak is made possible as Cre recombinase activity is under control of the skin-specific keratin-14 promoter. In addition, Cre is fused to the hormone binding domain of the oestrogen receptor (ER
T2
) and only induced in the presence of 4OHT ( Figure 1A ) (7). K14 mice were used to control for effects of Cre expression and 4OHT treatment. Treatment of K14 mice with TPA led to an increase in FAK expression within the skin, which was predominantly seen within the proliferative matrix region of the hair follicles and outer root sheath or bulge region ( Figure 1B ). This increase in FAK expression was also seen in anagen hair follicles during the first hair cycle (Supplementary Figure 1 , available at Carcinogenesis Online). Treatment of K14 mice with TPA also resulted in a thickening of the epidermis ( Figure 1C ) and quantitative analysis showed a small but significant reduction in the thickness of the epidermis from the TPA-treated K14/FAK fl/fl mice ( Figure 1C and 1D ). This was associated with a reduced proliferation in the basal keratinocytes as determined by Ki67 positivity ( Figure 1E ).
FAK is required for LRC mobilization
TPA is also known to initiate the proliferation of slow cycling putative stem cells from within the bulge region of the hair follicle (18), and it is the expansion of these cells that gives rise to papillomas in the chemically induced mouse model (12, 19) . As stem cells divide very infrequently in the adult mouse epidermis, DNA LRCs have been used to mark stem cell populations (20, 21) . Injection of BrdU into neonatal mice, which are undergoing rapid tissue expansion, results in the labelling of all dividing cells. LRCs are those cells that have retained the label in adult life and represent cells that are not dividing or have undergone limited cell division but retain regenerative capacity (22) . The hair follicles within the tail epidermis are larger than in the dorsal skin and therefore have a larger number of LRCs, thus facilitating quantitative analysis (17, 21) . These LRCs within the hair follicle are mainly located within the non-cycling region below the sebaceous gland in the tail epidermis (17) (Figure 2A , visualized in red).
We monitored the number of LRCs following TPA treatment in tail epidermis whole mounts from K14 and K14/FAK fl/fl mice. TPA treatment resulted in a loss (exit from their quiescent state) of the longterm labelled cells from the hair follicles in K14 mice (Figure 2A , P = 0.0122), whereas there was no significant reduction in K14/FAK fl/fl mice ( Figure 2B , P = 0.1376). FAK loss did not alter the number of LRCs in untreated K14 and K14/FAK fl/fl mice indicating that FAK does not regulate maintenance of the LRC population but regulates their ability to respond to external stimuli such as TPA. 
Src kinase activity is required for LRC mobilization
The non-receptor tyrosine kinase Src is a major binding partner of FAK (23) . Activation and autophosphorylation of FAK leads to a high-affinity binding site for Src, which in turn phosphorylates a number of residues within FAK that are required for its optimal kinase activity. In addition, the Src-dependent phosphorylation of FAK leads to the generation of binding sites for a number of other scaffolding proteins and kinases and the FAK/Src complex therefore controls a number of downstream signalling pathways (23, 24) . Src family kinases are known to play a role in controlling epidermal proliferation (25) (26) (27) , and we have shown previously that treatment with the Src kinase inhibitor AZD0530 also reduces chemically induced papilloma formation (15) . Therefore, we asked whether the Src/FAK signalling axis could regulate LRC mobilization. Three main Src family members are present in the epidermis (Src, Fyn and Yes), and initially, we looked at the effect of either homozygous deletion of fyn or yes in Redundancy within the Src family members is known; however, it was not possible to address this genetically due to problems with the viability of the double and triple mutants. Therefore, we used the small molecule kinase inhibitor AZD0530 that inhibits all Src family kinases (30) . Prior treatment of animals with AZD0530 resulted in a significant attenuation of the ability of TPA to initiate division of the LRCs ( Figure 2C ). As AZD0530 also inhibits c-Abl, we used imatinib a c-Abl inhibitor that does not inhibit Src family members (31) . Prior treatment of mice with imatinib did not alter TPA-induced LRC mobilization ( Figure 2D ) indicating that the effects of AZD0530 cannot be attributed to inhibition of c-Abl. Thus, both Src kinase activity and FAK regulate the ability of LRCs within the hair follicle to initiate cell division in response to TPA.
FAK is required for β-catenin-driven LRC mobilization
Wnt signalling via β-catenin activation is a well-described regulator of stem cells in the skin (8, 10) and recent reports have suggested a link between the Wnt signalling pathway and FAK (32) (33) (34) . Therefore, to address whether FAK can directly regulate the ability of β-catenin to mobilize LRC within the skin, we used mice expressing a dominant allele of the β-catenin gene in which exon 3, which contains the phosphorylation sites responsible for its degradation, were flanked by loxP sequences (Catnb ∆ex3 ) (13) . Crossing these mice with the K14 mice, allowed us to conditionally express the stabilized β-catenin in the epidermis of adult skin following treatment with 4OHT (K14/ ), thus alleviating the problem of perinatal death when using non-inducible K14/Catnb ∆ex3 mice (35) . Increased expression of β-catenin was confirmed by immunohistochemistry ( Figure 3A) . The most dramatic increases in β-catenin expression (both cytoplasmic and nuclear) were seen in the matrix region and the outer root sheath with very little nuclear β-catenin seen in the epidermis ( Figure 3A) . Activation of β-catenin increased the number of hair follicles, and there was also a thickening of the skin, which was due to an increase in thickness of the dermis as there was little change in the interfollicular epidermis ( Figure 3A) . The phenotype observed was more marked than in mice expressing a stabilized β-catenin transgene (36, 37) and may reflect the more efficient expression of the endogenous protein in our mice, as we observed strong nuclear staining for β-catenin throughout the hair follicles ( Figure 3A) . To determine the effect of fak deletion on the β-catenin-driven changes in the skin, we crossed the K14/Catnb ∆ex3 mice with the K14/FAK fl/fl mice and analysed the skin in the resulting K14/FAK fl/fl /Catnb ∆ex3 progeny. Deletion of FAK had no effect on either the number of hair follicles or the thickness of the dorsal skin ( Figure 3B and 3C) . However, analysis of the number of LRCs in the follicles showed that there was a significant reduction in LRCs upon activation of β-catenin in the K14/Catnb ∆ex3 mice and this was not seen in the K14/FAK fl/fl /Catnb ∆ex3 mice ( Figure 4A ). Thus, when β-catenin is constitutively expressed in the K14/Catnb ∆ex3 mice, FAK is required specifically for the ability of β-catenin to mobilize the bulge stem cells. Pre-treatment of K14/Catnb ∆ex3 mice with the Src inhibitor AZD0530 prior to induction of β-catenin stabilization also resulted in a partial abrogation of the loss of LRCs ( Figure 4B ). So, FAK and its binding partner Src can regulate the mobilization of LRCs downstream of β-catenin activation. Interestingly, expression of both FAK and Src was increased in the skin upon activation of β-catenin ( Figure 4C , compare low levels of FAK in normal skin shown in Figure 1B ), indicating that although FAK and Src can regulate β-catenin mobilization of LRC their expression is in turn increased when β-catenin activity is high.
FAK regulates β-catenin transcriptional activity
To address the mechanism whereby FAK regulates β-catenin signalling, we first looked at the localization of β-catenin in the skin. We observed a marked increase in the nuclear localization of β-catenin following TPA treatment of K14 mice ( Figure 5A ). Cells expressing nuclear β-catenin were found throughout the different layers of the thickened interfollicular epidermis ( Figure 5A ) and the outer root sheath of the anagen follicles ( Figure 5A ). The greatest increase in β-catenin expression was seen in the highly proliferative matrix region where increased cytoplasmic as well as nuclear β-catenin was seen ( Figure 5A ). However, treatment of K14/FAK fl/fl mice with TPA resulted in a different pattern of β-catenin expression: increased expression at cell membranes and in the cytoplasm was seen throughout the interfollicular epidermis and outer root sheath, but nuclear β-catenin was only seen in the matrix region at the base of the hair follicle ( Figure 5A ). Thus, FAK regulates the nuclear accumulation of β-catenin in response to TPA in a distinct subpopulation of cells. To directly address whether FAK can control the transcriptional activity of β-catenin, keratinocytes were isolated from K14/FAK fl/fl mice and treated with 4OHT to induce FAK deletion ( Figure 1A ). Following treatment with Wnt3a, qRT-PCR was then carried out on known targets of the Wnt/β-catenin pathway, c-Myc, axin2 and Tcf7. 4OHT alone had no effect on the expression of Wnt targets ( Figure 5B ), and further controls were carried out in keratinocytes from K14 mice showing that 4OHT treatment alone did not prevent Wnt3a induction of Wnt targets in wild-type keratinocytes (Supplementary Figure 3, available at Carcinogenesis Online). Increased expression of c-Myc, axin2 and Tcf7 was seen following Wnt3a treatment and this was blocked in the K14/FAK fl/fl keratinocytes lacking FAK following treatment with 4OHT ( Figure 5B ). c-Myc expression in the skin is known to be increased following TPA treatment (38) and c-Myc has been shown to regulate epidermal stem cell mobilization (39, 40) . We, therefore, looked at c-Myc expression in the skin following treatment of both K14 and K14/FAK fl/fl mice with TPA. There was a significant increase in c-Myc expression throughout the epidermis and hair follicles following TPA treatment of K14 mice. In untreated K14/ FAK fl/fl mice, there was very little c-Myc expression and no increase in expression was seen following TPA treatment ( Figure 5C ). Not all Wnt targets were down regulated as Sox9 was still inducibly expressed following TPA treatment in the K14/FAK fl/fl mice (results not shown). Thus, FAK is required for the nuclear translocation and activation of β-catenin and prevents increased expression of c-Myc in the skin following TPA treatment.
Discussion
In this study, we have identified a novel role for FAK in the control of the epidermal stem cell compartment in vivo via a mechanism that involves cross-talk with the Wnt/β-catenin pathway. FAK acts to control the nuclear localization of β-catenin and the transcriptional regulation of key targets in the skin such as c-Myc. In addition, we identify a feedback loop in which β-catenin activity regulates the expression of FAK in the skin.
Little is known about the role of FAK in the epidermis. Keratinocytespecific deletion of FAK in the mouse using a keratin 5 promoter led to irregularities in the first hair cycle and a thinning of the epidermis in newborn pups, whereas in the adult mouse, there were reduced numbers of sebaceous glands (41) . This suggests that FAK can control different cell lineages within the epidermis but in a restricted manner with effects being most evident during the first hair cycle. Using the K14 promoter, we saw no gross abnormalities in the skin of adult K14/FAK fl/fl mice. However, upon addition of TPA, there was a reduction in epidermal thickening and abrogation of LRC mobilization in the K14/FAK fl/fl mice indicating that FAK is important in the skin during response to stress and/or external stimuli. The expression of FAK is restricted within the skin to the proliferative matrix region of the hair follicles and the outer root sheath or bulge region and is increased in anagen hair follicles induced either during the normal hair cycle or in response to proliferative signals such as TPA or β-catenin activation. Interestingly, the expression of Src is also regulated in a similar manner with increased expression seen in anagen hair follicles (15) . However, the direct signals that control FAK and Src expression within the skin are not known.
The role of β-catenin in hair follicle development is well documented (36, 37, (42) (43) (44) . It can act directly on the stem cells of the follicle to induce their mobilization or exit from a quiescent state to provide proliferating transit amplifying cells (45) . We saw a loss of LRCs upon activation of β-catenin. This is in contrast with the report of Lowry and co-workers who reported that the stem cell niche remained constant upon continual activation of β-catenin. These differences most probably result from the level of β-catenin activation in the two studies. The low level of β-catenin activation achieved by Lowry and co-workers allows for activation of the stem cells and entry into anagen. However, the stem cell niche can return to its quiescent state through inhibitory signals from the niche environment that overcomes the β-catenin activation (45) . In our experimental model, it is probably that the much higher levels of β-catenin activation have overridden the inhibitory effects of the niche with the resulting loss of stem cells, accompanied by a large increase in ectopic follicle formation. Indeed, loss of LRC expression in the bulge has also been seen after prolonged β-catenin activation (46) and expansion of the bulge stem cells has been reported following 4OHT treatment of the same K14/Catnb ∆ex3 mice (12) . In this study, we have identified a novel role for FAK in regulating β-catenin-induced mobilization of LRCs.
Very little is known about the interplay between FAK and Wnt/β-catenin signalling. We have identified a role for FAK in controlling the nuclear localization and transcriptional activity of β-catenin in the skin, which is restricted to a subpopulation of cells within the hair follicle. In addition, the expression of FAK is also upregulated following constitutive activation of β-catenin in the skin suggesting that there is a complex feedback loop between the two pathways, which regulates the fate of the epidermal cells and that FAK can modulate β-catenin signalling within the skin in response to external stimuli such as phorbol ester treatment. Previous studies have shown that FAK has been shown to synergize with Dvl2, a key component of Wnt signalling, to control TCF transcriptional activity via the Grb2 pathway (32) . In addition, FAK has been shown to regulate gene expression of the ligand Wnt3a in the developing neural plate in Xenopus laevis (33) , whereas in the skin, FAK is involved downstream of ROCK in the regulation of β-catenin expression (34) . Interestingly, there is also evidence that Src kinase activity can regulate the nuclear localization and transcriptional activity of β-catenin (47) (48) (49) suggesting that the FAK/Src signalling axis may be important. In support of this, we were able to show that treatment with the Src inhibitor AZD0530 was able to prevent LRC mobilization as effectively as genetic deletion of fak.
β-catenin has been identified as a regulator of cancer stem cells in the skin carcinogenesis model with deletion of β-catenin resulting in a loss of the CD34-positive stem cells and tumour regression (12) . In addition, loss of β-catenin also prevented tumour initiation driven by dimethylbenzanthracene/TPA treatment, and we propose that loss of FAK in the epidermis acts to disrupt the β-catenin-dependent regulation of LRC within the bulge thereby preventing tumour formation. c-Myc is a β-catenin target gene that plays an important role in the epidermis where it is known to regulate stem cell mobilization (39, 40) . We show that induction of c-Myc expression in the epidermis following TPA treatment is prevented in K14/FAK fl/fl mice that may contribute to the effect of fak deletion on LRC mobilization. Interestingly, c-Myc is also important for the initiation of tumour formation in the skin carcinogenesis model, with mice lacking c-Myc in the epidermis being resistant to the formation of papillomas (50) . It is thought to co-operate with cells within the bulge region that have acquired an activating H-Ras mutation via a mechanism that involves regulation of p21 levels (50) . Therefore, in addition to the effects on LRC mobilization, the reduction in c-Myc levels in TPA-treated skin from the K14/FAK fl/fl mice would also contribute to the reduction in the number of papillomas we observed in the K14/FAK fl/fl mice. In an attempt to understand the role of FAK in the formation of chemically induced tumours in the skin, we have revealed a novel role for this kinase in regulating Wnt/β-catenin signalling in the epidermis and the regulation of LRCs. Loss of FAK also prevents APC-driven tumourigenesis in the intestine (51) raising the possibility that FAK (and Src) kinase inhibitors that are currently in clinical development may have potential as chemo-preventative agents in tumours driven by activation of Wnt/β-catenin signalling. Interestingly, a recent report showed that proliferation and expansion of cancer stem cells and the formation and growth of squamous cell carcinomas requires a balance between transforming growth factor-β and FAK/integrin signalling suggesting that elevated FAK expression in tumours may also control the proliferation of established tumours via regulation of different cancer stem cell subtypes (52) . Supplementary Figures 1-3 can be found at http://carcin.oxfordjournals.org/
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